whitepaper

Application note: High-throughput sialylation screening in combination with titer monitoring for expediting clone selection in cell-line development

Posted: 29 May 2020 | | No comments yet

Glycosylation is one of the most important post-translational modifications when developing new biologics. It has a considerable impact on product performance and variability and is therefore a critical quality attribute (CQA), influencing product safety and efficacy.

Protein glycosylation can affect isolation and purification steps (process consistency), pharmacokinetics (half-life) properties and in vitro stability (product shelf-life). Sialylation is especially important as it significantly affects the safety and efficacy of therapeutic glycoproteins.











    To read this application note in full, please complete the form below. By clicking submit you confirm that you accept our terms and conditions and privacy policy.


    *

    *

    *

    *

    *

    *

    *

    *

    This content is provided to you for free thanks to the kind support of our sponsor: ForteBio

    I am happy for my details to be shared with the sponsors

    Related organisations